Skip to content

Study · Randomized controlled trial · n = 50 · 2007

2 results

Comparison of the effect of gonadotropin-releasing hormone analog (Diphereline) and Cabergoline (Dostinex) treatment on uterine myoma regression.

Melli MS, Farzadi L, Madarek EO

Saudi medical journal1 Mar 2007Cited by 17 (Europe PMC)

PMID17334477 (opens in a new tab)PepBankPUB-17334477
Publisher pageAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanRandomized controlled trialSafety outcome

    In women with uterine myoma, fewer adverse effects were noted with cabergoline than with Diphereline.

    In plain wordsIn women with uterine myoma, fewer side effects were noted with cabergoline than with Diphereline.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    IncreaseAdverse effects relative to cabergoline
    Study

    n = 50

    Comparator
    Cabergoline
    Outcome group
    Adverse events · Reproductive and sexual health
    Studied dose
    3.75 mg every 28 days, four administrationsAs given in this study (human).

    Source sentences

    Summary
    The Cabergoline was well tolerated and fewer adverse effects were noted.
    2 context sentences
    Summary · context
    Fifty women with uterine myoma, who met the criteria of the study thoroughly, were randomly allocated into 2 equal groups to take either Diphereline or Cabergoline.
    Summary · context
    The first Group took 3.75 mg of Diphereline 4 times every 28 days and the second group took 0.5 mg of Cabergoline once a week for 6 weeks.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In women with uterine myoma, Diphereline reduced individual tumor nodule volume by 21-97%.

    In plain wordsIn women with uterine myoma, Diphereline reduced individual tumor nodule volume by 21-97%.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    DecreaseMyoma nodule volume reduction
    Study

    n = 25

    Outcome group
    Tumor growth · Reproductive and sexual health
    Studied dose
    3.75 mg every 28 days, four administrationsAs given in this study (human).

    Measurements

    Nodule volume reduction
    21 to 97%
    Diphereline

    Source sentences

    Summary
    The gonadotropin releasing hormone agonist group all responded to the treatment, and volume reduction rate of the individual tumor nodule varied from 21-97%.
    2 context sentences
    Summary · context
    Fifty women with uterine myoma, who met the criteria of the study thoroughly, were randomly allocated into 2 equal groups to take either Diphereline or Cabergoline.
    Summary · context
    The first Group took 3.75 mg of Diphereline 4 times every 28 days and the second group took 0.5 mg of Cabergoline once a week for 6 weeks.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.